Functionalization of Mesoporous Carbon by Bovine Serum Albumin for Application in an Electrochemically Controlled Delivery System of Imatinib Anticancer Drug.
{"title":"Functionalization of Mesoporous Carbon by Bovine Serum Albumin for Application in an Electrochemically Controlled Delivery System of Imatinib Anticancer Drug.","authors":"Zahra Zangeneh, Bahare Sabeti, Fereshteh Chekin","doi":"10.2174/0109298673476176260824045519","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Imatinib (IM) is a tyrosine kinase inhibitor that targets the growth factor receptors. IM has demonstrated remarkable clinical efficacy across multiple cancer types. IM abrogates the activity of the Bcr-Abl oncoprotein, leading to the inhibition of cell proliferation and induction of apoptosis. However, side effects may negatively affect its efficiency.</p><p><strong>Objective: </strong>This prompted us to incorporate IM into nanostructured Bovine Serum Albumin- Coated Mesoporous carbon carriers (BSA/CMK-3) and to evaluate the electrochemically controlled release of the IM@BSA/CMK-3 nanoformulation in an in vitro model.</p><p><strong>Methods: </strong>The physicochemical characteristics of the IM@BSA/CMK-3 nanocapsules were examined using Field-Emission Scanning Electron Microscopy (FE-SEM), Ultraviolet- Visible (UV-Vis), Fourier Transform Infrared (FT-IR), X-ray Diffraction (XRD), and cyclic voltammetry analyses.</p><p><strong>Results: </strong>It was found that BSA/CMK-3 is an efficient carrier with IM loading as much as 84.6% in 0.1 M phosphate-buffered solution (PBS, pH 7.0) for 3 hours. BSA/CMK-3, due to the presence of functional groups (amino and carboxyl) in BSA, forms strong hydrogen bonds with the IM drug. We demonstrated that BSA/CMK-3 is a sensitive and efficient platform, and that BSA increases the stability of the IM@BSA/CMK-3 interface-- modified Screen-Printed Carbon Electrode (SPCE) and controls the release of the IM drug from the IM@BSA/CMK-3 hybrid. Furthermore, 81.4% of IM could be released upon application of +0.9 V for 2 hours at the IM@BSA/CMK-3 interface into PBS (0.1 M, pH 4.0). Furthermore, kinetic models were evaluated, and it was found that the drug release was best fit to the Higuchi model.</p><p><strong>Discussion: </strong>The BSA/CMK-3 nanohybrid, due to the presence of functional groups-rich BSA, seemed to provide effective loading and controlled electrochemical release of the IM drug.</p><p><strong>Conclusion: </strong>The electrochemically released IM drug loaded onto BSA/CMK-3 offers substantial potential for drug delivery applications.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673476176260824045519","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Imatinib (IM) is a tyrosine kinase inhibitor that targets the growth factor receptors. IM has demonstrated remarkable clinical efficacy across multiple cancer types. IM abrogates the activity of the Bcr-Abl oncoprotein, leading to the inhibition of cell proliferation and induction of apoptosis. However, side effects may negatively affect its efficiency.
Objective: This prompted us to incorporate IM into nanostructured Bovine Serum Albumin- Coated Mesoporous carbon carriers (BSA/CMK-3) and to evaluate the electrochemically controlled release of the IM@BSA/CMK-3 nanoformulation in an in vitro model.
Methods: The physicochemical characteristics of the IM@BSA/CMK-3 nanocapsules were examined using Field-Emission Scanning Electron Microscopy (FE-SEM), Ultraviolet- Visible (UV-Vis), Fourier Transform Infrared (FT-IR), X-ray Diffraction (XRD), and cyclic voltammetry analyses.
Results: It was found that BSA/CMK-3 is an efficient carrier with IM loading as much as 84.6% in 0.1 M phosphate-buffered solution (PBS, pH 7.0) for 3 hours. BSA/CMK-3, due to the presence of functional groups (amino and carboxyl) in BSA, forms strong hydrogen bonds with the IM drug. We demonstrated that BSA/CMK-3 is a sensitive and efficient platform, and that BSA increases the stability of the IM@BSA/CMK-3 interface-- modified Screen-Printed Carbon Electrode (SPCE) and controls the release of the IM drug from the IM@BSA/CMK-3 hybrid. Furthermore, 81.4% of IM could be released upon application of +0.9 V for 2 hours at the IM@BSA/CMK-3 interface into PBS (0.1 M, pH 4.0). Furthermore, kinetic models were evaluated, and it was found that the drug release was best fit to the Higuchi model.
Discussion: The BSA/CMK-3 nanohybrid, due to the presence of functional groups-rich BSA, seemed to provide effective loading and controlled electrochemical release of the IM drug.
Conclusion: The electrochemically released IM drug loaded onto BSA/CMK-3 offers substantial potential for drug delivery applications.
期刊介绍：
Aims & Scope
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
